Literature DB >> 8500108

Application of the direct beta counter Matrix 96 for cytotoxic assays: simultaneous processing and reading of 96 wells using a 51Cr-retention assay.

G G Hillman1, N Roessler, R S Fulbright, J E Pontes, G P Haas.   

Abstract

To assess the cytotoxic activity of immune cells, we have developed a 51Cr-retention assay in which the radioactivity retained by 51Cr-labeled target cells, following coincubation with cytotoxic cells, is monitored using the automated Matrix 96 beta counter. The Matrix 96 is designed for simultaneously counting 96 samples isolated from a 96-well microplate. It uses 96 uniform and independent detectors operating on the principle of avalanche gas ionization in the Geiger-Muller mode. Samples must be dry because the detectors are of the open-window type. Therefore, samples from the 96 wells of the microplate are simultaneously harvested onto a filter using the MicroMate 196, a 96-well cell harvester, dried and quantified in the Matrix 96. Usually the 51Cr isotope is measured by the detection of gamma radiation in gamma counters. The Matrix 96, however, monitors Auger electrons, which are also emitted by 51Cr. We have shown that the retention assay can be used to monitor the cytotoxic activity of activated lymphocytes including lymphokine-activated killer cells and tumor-infiltrating lymphocytes against various tumor cell lines. This assay is most suitable for experiments in which low E/T ratios are sufficient to detect highly cytotoxic cells, such as clone screening in cloning assays or in limiting-dilution analysis assays. These assays involve processing and reading large numbers of microplates. In this case, the retention assay monitored in the Matrix 96 will improve the work flow and decrease the amount of radioactive waste.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500108     DOI: 10.1007/BF01742250

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  12 in total

1.  Dot-blot hybridization: quantitative analysis with direct beta counting.

Authors:  M A Sognier; R E Neft; A L Roe; R L Eberle; J A Belli
Journal:  Biotechniques       Date:  1991-10       Impact factor: 1.993

2.  The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.

Authors:  L L Lanier; A M Le; C I Civin; M R Loken; J H Phillips
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

3.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.

Authors:  K T Brunner; J Mauel; J C Cerottini; B Chapuis
Journal:  Immunology       Date:  1968-02       Impact factor: 7.397

4.  Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.

Authors:  M R Albertini; K R Oettel; G Weil-Hillman; M J Lindstrom; K Schell; J A Hank; P M Sondel
Journal:  J Biol Response Mod       Date:  1990-10

Review 5.  How killer cells kill.

Authors:  J D Young; Z A Cohn
Journal:  Sci Am       Date:  1988-01       Impact factor: 2.142

6.  Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.

Authors:  G Weil-Hillman; J A Hank; N S Rosenthal; P M Sondel
Journal:  J Biol Response Mod       Date:  1988-10

7.  Measurement of cytotoxicity by target cell release and retention of the fluorescent dye bis-carboxyethyl-carboxyfluorescein (BCECF).

Authors:  M A Kolber; R R Quinones; R E Gress; P A Henkart
Journal:  J Immunol Methods       Date:  1988-04-06       Impact factor: 2.303

8.  Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.

Authors:  G Weil-Hillman; K Schell; D M Segal; J A Hank; J A Sosman; P M Sondel
Journal:  J Immunother (1991)       Date:  1991-08

9.  Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis.

Authors:  P Fisch; M Malkovsky; E Braakman; E Sturm; R L Bolhuis; A Prieve; J A Sosman; V A Lam; P M Sondel
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.